437 related articles for article (PubMed ID: 10529234)
1. Both ATP sites of human P-glycoprotein are essential but not symmetric.
Hrycyna CA; Ramachandra M; Germann UA; Cheng PW; Pastan I; Gottesman MM
Biochemistry; 1999 Oct; 38(42):13887-99. PubMed ID: 10529234
[TBL] [Abstract][Full Text] [Related]
2. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
3. Functionally similar vanadate-induced 8-azidoadenosine 5'-[alpha-(32)P]Diphosphate-trapped transition state intermediates of human P-glycoprotin are generated in the absence and presence of ATP hydrolysis.
Sauna ZE; Smith MM; Muller M; Ambudkar SV
J Biol Chem; 2001 Jun; 276(24):21199-208. PubMed ID: 11287418
[TBL] [Abstract][Full Text] [Related]
4. Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity.
Julien M; Gros P
Biochemistry; 2000 Apr; 39(15):4559-68. PubMed ID: 10758006
[TBL] [Abstract][Full Text] [Related]
5. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites.
Urbatsch IL; Beaudet L; Carrier I; Gros P
Biochemistry; 1998 Mar; 37(13):4592-602. PubMed ID: 9521779
[TBL] [Abstract][Full Text] [Related]
6. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335).
Chen KG; Lacayo NJ; Durán GE; Cohen D; Sikic BI
Mol Pharmacol; 2000 Apr; 57(4):769-77. PubMed ID: 10727524
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of conserved carboxylate residues in the nucleotide binding sites of P-glycoprotein.
Urbatsch IL; Julien M; Carrier I; Rousseau ME; Cayrol R; Gros P
Biochemistry; 2000 Nov; 39(46):14138-49. PubMed ID: 11087362
[TBL] [Abstract][Full Text] [Related]
8. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
Dey S; Hafkemeyer P; Pastan I; Gottesman MM
Biochemistry; 1999 May; 38(20):6630-9. PubMed ID: 10350482
[TBL] [Abstract][Full Text] [Related]
9. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
10. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.
Shepard RL; Winter MA; Hsaio SC; Pearce HL; Beck WT; Dantzig AH
Biochem Pharmacol; 1998 Sep; 56(6):719-27. PubMed ID: 9751076
[TBL] [Abstract][Full Text] [Related]
11. Functional reassembly of ATP-dependent xenobiotic transport by the N- and C-terminal domains of RLIP76 and identification of ATP binding sequences.
Awasthi S; Cheng JZ; Singhal SS; Pandya U; Sharma R; Singh SV; Zimniak P; Awasthi YC
Biochemistry; 2001 Apr; 40(13):4159-68. PubMed ID: 11300797
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1.
Gao M; Cui HR; Loe DW; Grant CE; Almquist KC; Cole SP; Deeley RG
J Biol Chem; 2000 Apr; 275(17):13098-108. PubMed ID: 10777615
[TBL] [Abstract][Full Text] [Related]
13. Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein.
Maki N; Moitra K; Ghosh P; Dey S
J Biol Chem; 2006 Apr; 281(16):10769-77. PubMed ID: 16505485
[TBL] [Abstract][Full Text] [Related]
14. Analysis of catalytic carboxylate mutants E552Q and E1197Q suggests asymmetric ATP hydrolysis by the two nucleotide-binding domains of P-glycoprotein.
Carrier I; Julien M; Gros P
Biochemistry; 2003 Nov; 42(44):12875-85. PubMed ID: 14596601
[TBL] [Abstract][Full Text] [Related]
15. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase.
Rao US
Biochemistry; 1998 Oct; 37(42):14981-8. PubMed ID: 9778376
[TBL] [Abstract][Full Text] [Related]
16. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein.
Hafkemeyer P; Dey S; Ambudkar SV; Hrycyna CA; Pastan I; Gottesman MM
Biochemistry; 1998 Nov; 37(46):16400-9. PubMed ID: 9819232
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the properties of the N-terminal nucleotide-binding domain of human P-glycoprotein.
Booth CL; Pulaski L; Gottesman MM; Pastan I
Biochemistry; 2000 May; 39(18):5518-26. PubMed ID: 10820025
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites.
Ohnuma S; Chufan E; Nandigama K; Jenkins LM; Durell SR; Appella E; Sauna ZE; Ambudkar SV
Biochemistry; 2011 May; 50(18):3724-35. PubMed ID: 21452853
[TBL] [Abstract][Full Text] [Related]
19. Functional expression of multidrug resistance protein 1 in Pichia pastoris.
Cai J; Daoud R; Georges E; Gros P
Biochemistry; 2001 Jul; 40(28):8307-16. PubMed ID: 11444977
[TBL] [Abstract][Full Text] [Related]
20. Function of the ABC signature sequences in the human multidrug resistance protein 1.
Ren XQ; Furukawa T; Haraguchi M; Sumizawa T; Aoki S; Kobayashi M; Akiyama S
Mol Pharmacol; 2004 Jun; 65(6):1536-42. PubMed ID: 15155846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
